CJC-1295 + GHRP-6 Stack vs Gonadorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profileGonadorelin
Synthetic form of endogenous gonadotropin-releasing hormone (GnRH) that stimulates LH and FSH release from the anterior pituitary. Used in TRT protocols to maintain testicular function and prevent atrophy during exogenous testosterone administration. Preserves spermatogenesis and endogenous testosterone production capacity.
Full profile| CJC-1295 + GHRP-6 Stack | Gonadorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 | GnRH, gonadotropin-releasing hormone, Factrel, Lutrepulse |
| Evidence | Research-stage | Research-stage |
| Dosing range | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) | 50mcg–200mcg mcg, 2–3x per week subcutaneous |
| Administration | Subcutaneous injection | Subcutaneous injection, Intranasal (pulsatile delivery) |
| Key side effects | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) | Injection site reactions, Headache, Nausea, Flushing |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; Gonadorelin — Subcutaneous injection, Intranasal (pulsatile delivery).
- Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); Gonadorelin is 2–3x per week subcutaneous.
How each works
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
Gonadorelin
Gonadorelin directly binds GnRH receptors in the anterior pituitary to trigger LH and FSH secretion, which in turn stimulates Leydig cells for testosterone production and maintains spermatogenesis. Used as a TRT adjunct, pulsatile gonadorelin administration mimics natural hypothalamic GnRH to prevent testicular suppression associated with exogenous androgen use.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.